Patent application number | Description | Published |
20080226754 | METHOD FOR TREATMENT OF CARTILAGE DISORDERS WITH CENTELLA EXTRACT - The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of | 09-18-2008 |
20080268016 | Engineered Renal Tissue - Biocompatible tissue repair implant devices and their methods of use are provided for repairing a diseased kidney tissue. The present invention relates to methods of removing a portion of kidney tissue from a host or donor, mincing it, placing it on a bioresorbable scaffold, and implanting the scaffold into a defect site in a kidney of a host or patient for use in the treatment of degenerative kidney diseases. The compositions and methods provide a pluripotent milieu for the de-novo generation of renal tubular structures in the replacement of diseased kidney tissue. The processes and devices are useful in the treatment of medical conditions and diseases relating to the kidneys such as trauma, necrosis, and both acute and chronic forms of renal failure. | 10-30-2008 |
20090155245 | Treatment for Organ Regeneration with Combination of Drug and Biologics - Combination therapies of drugs and biologics for treatment of acute and chronic organ degeneration are disclosed. More specifically, the use of morphogens, stem cells, and anti-inflammatories or inhibitors for the renin-angiotensin-aldosterone system (RAAS) for the treatment of acute and chronic renal disease is disclosed. | 06-18-2009 |
20090162351 | Transdiscal administration of inhibitors of p38 MAP kinase - The present invention relates to methods, formulations and kits for administering a p38 MAP kinase inhibitor or other therapeutic agent into an intervertebral disc, such as a diseased disc, for example, for purposes of prevention and treatment of degenerative and other disorders. | 06-25-2009 |
20090162376 | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints - The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent. | 06-25-2009 |
20090275129 | TISSUE ENGINEERED BLOOD VESSELS - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 11-05-2009 |
20110060419 | MEDICAL DEVICES WITH GALVANIC PARTICULATES - Implantable medical devices having galvanic particulates are disclosed. The particulates may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The devices may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, and tissue regeneration promoting. The medical devices may be used as bone implants. | 03-10-2011 |
20110143429 | TISSUE ENGINEERED BLOOD VESSELS - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 06-16-2011 |
20110223205 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING UMBILICAL DERIVED CELLS - This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient. | 09-15-2011 |
20110230406 | AFFINITY PEPTIDES TOWARD BMP-2 - We have disclosed affinity peptides toward BMP-2. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for BMP-2. | 09-22-2011 |
20120089232 | MEDICAL DEVICES WITH GALVANIC PARTICULATES - Implantable medical devices having galvanic particulates are disclosed. The particulates may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination. | 04-12-2012 |
20130196431 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130196438 | TISSUE ENGINEERED BLOOD VESSELS - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130196439 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130196440 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130203168 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-08-2013 |
20130295184 | MEDICAL DEVICES WITH GALVANIC PARTICULATES - Implantable medical devices having galvanic particulates are disclosed. The particulate may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination. | 11-07-2013 |
Patent application number | Description | Published |
20120116137 | SINGLE LOOP MULTISTAGE FUEL PRODUCTION - Synthetic fuels are produced from synthesis gas in a four-stage reactor system with a single recycle loop providing the requisite thermal capacity to moderate the high heat release of the reactions and to provide the reactants and reaction environments for the efficient operation of the process. The first stage converts a portion of the synthesis gas to methanol, the second stage converts the methanol to dimethylether, the third stage converts the methanol and dimethylether to fuel and the fourth stage converts the high melting point component, durene, and other low volatility aromatic components such as tri- andtetra-methylbenzenes to high octane branched paraffins. The four-stage catalyst used for hydrotreating is resistant to CO poisoning. The reactions i produce water as a side product that is carried through to a high pressure separator after the fourth stage. The streams from the separator are a liquid fuel stream, a water stream and a gaseous stream that contains light hydrocarbon gases and the unreacted synthesis gas. The larger part of this gas stream is recycled to the inlet of the first stage and mixed with the fresh synthesis gas stream. Alternatively, the fresh synthetic gas stream is mixed with the product of the second stage. The smaller part of the gas stream from the separator is sent to hydrocarbon recovery and to fuel gas used for providing preheat of various streams. The liquid fuel is sent for blending into fuel products, such as gasoline, jet fuel, or diesel, and the water stream can be sent, for example, to the synthesis gas producing plant for steam generation. | 05-10-2012 |
20130270483 | CATALYTICAL GASIFIER CONFIGURATION FOR BIOMASS PYROLYSIS - The invention relates to systems and methods for producing synthesis gas. In particular, the systems of the present invention include two catalytic reactors in series, a wet reformer/gasifier followed by a dry reformer. The systems produce synthesis gas with very little to no methane. | 10-17-2013 |
20140018587 | NOVEL FUEL COMPOSITION - This invention relates to fuel compositions for use in combustion engines, such as for motor vehicle and aircraft usage. The fuel composition contains at least 99.5% of aromatic hydrocarbons and paraffinic hydrocarbons. The composition also preferably contains no lead, no multi-ring compound (only single ring compounds are present), less than about 15 ppm sulfur, and/or less than about 5 ppm nitrogen species. The resulting fuel is a drop-in fuel that provides clean burning with little to no engine deposit, high lubricity, high stability, and low corrosion. | 01-16-2014 |
20140199213 | SINGLE LOOP MULTISTAGE FUEL PRODUCTION - Synthetic fuels are produced from synthesis gas in a four-stage reactor system with a single recycle loop providing the requisite thermal capacity to moderate the high heat release of the reactions and to provide the reactants and reaction environments for the efficient operation of the process. The first stage converts a portion of the synthesis gas to methanol, the second stage converts the methanol to dimethylether, the third stage converts the methanol and dimethylether to fuel and the fourth stage converts the high melting point component, durene, and other low volatility aromatic components such as tri- and tetra-methylbenzenes to high octane branched paraffins. The four-stage catalyst used for hydrotreating is resistant to CO poisoning. The reactions i produce water as a side product that is carried through to a high pressure separator after the fourth stage. The streams from the separator are a liquid fuel stream, a water stream and a gaseous stream that contains light hydrocarbon gases and the unreacted synthesis gas. The larger part of this gas stream is recycled to the inlet of the first stage and mixed with the fresh synthesis gas stream. Alternatively, the fresh synthetic gas stream is mixed with the product of the second stage. The smaller part of the gas stream from the separator is sent to hydrocarbon recovery and to fuel gas used for providing preheat of various streams. The liquid fuel is sent for blending into fuel products, such as gasoline, jet fuel, or diesel, and the water stream can be sent, for example, to the synthesis gas producing plant for steam generation. | 07-17-2014 |
Patent application number | Description | Published |
20090111831 | PHARMACEUTICAL COMPOSITIONS - Disclosed herein are novel compositions useful for the treatment of androgen dependant diseases. | 04-30-2009 |
20110034478 | Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs - The present invention provides a solid molecularly dispersed composition comprising a poorly water soluble and weakly basic azole antifungal compound and a pH sensitive polymer, pharmaceutical compositions, comprising the solid molecularly dispersed composition of the invention and methods of treating and/or preventing a fungal infection in a patient in need thereof comprising orally administering a pharmaceutical composition comprising a composition of the invention to a patient in need thereof. Preferably the antifungal, compound is posaconazole, and the pH sensitive polymer is HPMCAS. | 02-10-2011 |
20110123627 | HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS COMPRISING THE SAME - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material. | 05-26-2011 |
20150150990 | ORAL PHARMACEUTICAL COMPOSITIONS IN A SOLID DISPERSION COMPRISING PREFERABLY POSACONAZOLE AND HPMCAs - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature temperature (Tg) of less than about 110° C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. | 06-04-2015 |
Patent application number | Description | Published |
20140334295 | Symmetric Service Chain Binding - A plurality of network nodes are deployed in a network, each network node configured to apply a service function to traffic that passes through the respective network nodes. A controller generates information for a service chain that involves application to traffic of one or more service functions at corresponding ones of the plurality of network nodes along a forward path through the one or more network nodes. The controller identifies one or more of the service functions within the service chain that is stateful. When one or more of the service functions of the service chain is stateful, the controller generates information for a reverse path through the one or more service nodes for the one or more stateful service functions. The controller binds a forward chain identifier for the forward path with a reverse chain identifier for the reverse path for the service chain. | 11-13-2014 |
20140351452 | Chaining Service Zones by way of Route Re-Origination - Presented herein are techniques for use in a network environment that includes one or more service zones, each service zone including at least one instance of an in-line application service to be applied to network traffic and one or more routers to direct network traffic to the at least one service, and a route target being assigned to a unique service zone to serve as a community value for route import and export between routers of other service zones, destination networks or source networks via a control protocol. An edge router in each service zone or destination network advertises routes by its destination network prefix tagged with its route target. A service chain is created by importing and exporting of destination network prefixes by way of route targets at edge routers of the service zones or source networks. | 11-27-2014 |
20140365634 | Programmable Network Analytics Processing via an Inspect/Apply-Action Applied to Physical and Virtual Entities - Techniques are provided to programming network analytics processing in virtual and physical network devices, useful for software-defined networking (SDN). A controller, e.g., a so-called SDN controller, is configured to identify a control-plane or data-plane flow originating, terminating or transiting a physical or virtual network element. The controller generates one or more network analytics processing actions to be performed by the physical or virtual network element based on inspection of traffic by the physical or virtual network element. The controller forms or generates an inspect/apply-action message containing information identifying the control-plane or data-plane flow for inspection and the one or more network analytics processing actions to be performed. The inspect/apply-action message is sent to the physical or virtual network element. | 12-11-2014 |